MX2009007334A - Compuestos de amida del acido indol-3-carboxilico 6-substituido que tienen actividad antagonista biologica del receptor esfingosina-1-fosfato (s1p). - Google Patents
Compuestos de amida del acido indol-3-carboxilico 6-substituido que tienen actividad antagonista biologica del receptor esfingosina-1-fosfato (s1p).Info
- Publication number
- MX2009007334A MX2009007334A MX2009007334A MX2009007334A MX2009007334A MX 2009007334 A MX2009007334 A MX 2009007334A MX 2009007334 A MX2009007334 A MX 2009007334A MX 2009007334 A MX2009007334 A MX 2009007334A MX 2009007334 A MX2009007334 A MX 2009007334A
- Authority
- MX
- Mexico
- Prior art keywords
- sphingosine
- biological activity
- phosphate
- carboxylic acid
- acid amide
- Prior art date
Links
- 230000004071 biological effect Effects 0.000 title abstract 2
- -1 6-substituted indole-3-carboxylic acid amide compounds Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 229940121846 Sphingosine 1-phosphate receptor agonist Drugs 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88447007P | 2007-01-11 | 2007-01-11 | |
| PCT/US2008/050695 WO2008089015A1 (en) | 2007-01-11 | 2008-01-10 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009007334A true MX2009007334A (es) | 2009-07-15 |
Family
ID=39399972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009007334A MX2009007334A (es) | 2007-01-11 | 2008-01-10 | Compuestos de amida del acido indol-3-carboxilico 6-substituido que tienen actividad antagonista biologica del receptor esfingosina-1-fosfato (s1p). |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2125723A1 (enExample) |
| JP (1) | JP2010515750A (enExample) |
| KR (1) | KR20090101307A (enExample) |
| CN (1) | CN101668741A (enExample) |
| AU (1) | AU2008206495A1 (enExample) |
| CA (1) | CA2674946A1 (enExample) |
| MX (1) | MX2009007334A (enExample) |
| WO (1) | WO2008089015A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8524917B2 (en) * | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
| US20110009453A1 (en) * | 2008-03-17 | 2011-01-13 | Donello John E | s1p3 receptor inhibitors for treating inflammation |
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| EP2342205B1 (en) | 2008-08-27 | 2016-04-20 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| EP4148045A1 (en) | 2010-01-27 | 2023-03-15 | Arena Pharmaceuticals, Inc. | Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof |
| ES2558087T3 (es) | 2010-03-03 | 2016-02-01 | Arena Pharmaceuticals, Inc. | Procesos para la preparación de moduladores del receptor S1P1 y formas cristalinas de los mismos |
| TWI522361B (zh) * | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
| WO2017123826A1 (en) | 2016-01-14 | 2017-07-20 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| WO2018151834A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| CN110483437B (zh) * | 2018-05-14 | 2022-12-06 | 嘉兴维眸生物科技有限公司 | 一种含五元环的化合物及其制备和应用 |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| CN119751336A (zh) | 2018-09-06 | 2025-04-04 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2121394A1 (fr) * | 1971-01-08 | 1972-08-25 | Anvar | Procédé d'obtention de dérivés d'acides indole carboxyliques et produits préparables par ce procédé. |
| EP0146810A3 (de) | 1983-12-05 | 1987-05-13 | Solco Basel AG | Verfahren zur Herstellung von Sphingosinderivaten |
| US5110987A (en) | 1988-06-17 | 1992-05-05 | Emory University | Method of preparing sphingosine derivatives |
| ZA902794B (en) | 1989-04-18 | 1991-04-24 | Duphar Int Res | New 3-n substituted carbamoyl-indole derivatives |
| US5294722A (en) | 1992-04-16 | 1994-03-15 | E. R. Squibb & Sons, Inc. | Process for the preparation of imidazoles useful in angiotensin II antagonism |
| US5403851A (en) | 1994-04-05 | 1995-04-04 | Interneuron Pharmaceuticals, Inc. | Substituted tryptamines, phenalkylamines and related compounds |
| DE69728581D1 (de) | 1996-01-22 | 2004-05-13 | Fujisawa Pharmaceutical Co | Thiazolylbenzofuranderivate und ihre Verwendung als SRS-A- und Leukotrien-Antagonisten |
| JP4001929B2 (ja) | 1997-03-12 | 2007-10-31 | タカラバイオ株式会社 | スフィンゴシン類縁化合物 |
| AU9002298A (en) | 1997-09-11 | 1999-03-29 | Takara Shuzo Co., Ltd. | Sphingosine derivatives and medicinal composition |
| DE19753522A1 (de) | 1997-12-03 | 1999-06-10 | Boehringer Ingelheim Pharma | Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel |
| AP2001002228A0 (en) * | 1999-01-13 | 2001-09-30 | Millenium Pharmaceuticals Inc | Functionalized heterocycles as chemokine receptor modulators. |
| WO2001098301A1 (en) | 2000-06-20 | 2001-12-27 | Japan Tobacco Inc. | Pyrazolopyridine compounds and use thereof as drugs |
| WO2003000253A1 (en) | 2001-06-20 | 2003-01-03 | Wyeth | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| WO2003070691A1 (en) | 2002-02-21 | 2003-08-28 | Osaka Industrial Promotion Organization | N-hydroxycarboxamide derivative |
| JP2009526863A (ja) | 2006-02-15 | 2009-07-23 | アラーガン、インコーポレイテッド | スフィンゴシン−１−リン酸（ｓ１ｐ）受容体アンタゴニスト生物学的活性を有するアリールまたはヘテロアリール基を持つインドール−３−カルボン酸アミド、エステル、チオアミドおよびチオールエステル化合物 |
-
2008
- 2008-01-10 JP JP2009545669A patent/JP2010515750A/ja not_active Abandoned
- 2008-01-10 WO PCT/US2008/050695 patent/WO2008089015A1/en not_active Ceased
- 2008-01-10 AU AU2008206495A patent/AU2008206495A1/en not_active Abandoned
- 2008-01-10 MX MX2009007334A patent/MX2009007334A/es not_active Application Discontinuation
- 2008-01-10 KR KR1020097016762A patent/KR20090101307A/ko not_active Withdrawn
- 2008-01-10 CN CN200880007131A patent/CN101668741A/zh active Pending
- 2008-01-10 CA CA002674946A patent/CA2674946A1/en not_active Abandoned
- 2008-01-10 EP EP08727502A patent/EP2125723A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008206495A1 (en) | 2008-07-24 |
| KR20090101307A (ko) | 2009-09-24 |
| CA2674946A1 (en) | 2008-07-24 |
| EP2125723A1 (en) | 2009-12-02 |
| CN101668741A (zh) | 2010-03-10 |
| JP2010515750A (ja) | 2010-05-13 |
| WO2008089015A1 (en) | 2008-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009007334A (es) | Compuestos de amida del acido indol-3-carboxilico 6-substituido que tienen actividad antagonista biologica del receptor esfingosina-1-fosfato (s1p). | |
| MX2010007588A (es) | Compuestos de amida del acido indol-3-carboxilico 6-substituido que tienen actividad antagonista biologica del receptor de esfingosina-1-fosfato (s1p). | |
| WO2007112322A3 (en) | Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity | |
| WO2007095561A3 (en) | Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity | |
| WO2009035997A3 (en) | Benzo-fused heterocycles | |
| NO20092711L (no) | Metoder for anvendelse av cyclopaminanaloger | |
| TNSN08089A1 (en) | Substituted benzimidazoles and methods of preparation | |
| NO20091596L (no) | Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer | |
| NO20090581L (no) | Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer | |
| NO20085385L (no) | Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav | |
| MX2013005535A (es) | Compuesto de 3- (amino-aril) -piridina. | |
| WO2009003999A3 (en) | Chemical compounds | |
| NO20071314L (no) | Peptidiske vasopressinreseptoragonister | |
| NO20091741L (no) | Pyrazolinforbindelser som mineralkortikoidreceptorantagonister | |
| WO2008059370A3 (en) | Substituted bicyclocarboxyamide compounds | |
| NZ592382A (en) | Thioamide compounds, method of making and method of using thereof | |
| ATE520651T1 (de) | Substituierte phenylmethylbicyclocarbonsäureamidverbindungen | |
| WO2008152014A3 (en) | 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases | |
| NO20083845L (no) | 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer | |
| NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
| WO2009000832A3 (en) | Chemical compounds | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| NO20091052L (no) | Diaryleterderivater og anvendelser derav | |
| WO2008045371A3 (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
| WO2006113471A3 (en) | N-alkyl-azacycloalkyl nmda/nr2b antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |